Prevalence, cardiac phenotype and outcomes of TTR variants in the UK Biobank Population

13 May 2024 (16:51 - 17:00)

Organised by:

Video

Sign in for access options

Abstract

Slides

About the speaker

Doctor Nay Aung

Queen Mary University of London, London (United Kingdom of Great Britain & Northern Ireland)

6 More presentations in this session

Presentation thumbnail

International prevalence of transthyretin amyloid cardiomyopathy in high-risk patients with heart failure and preserved or mildly reduced ejection fraction

Doctor S. Yun Viladomat (Hospitalet De Llobregat, ES)

Abstract Slides Video

Presentation thumbnail

Age- and sex-related trends in transthyretin amyloid cardiomyopathy prevalence in older patients with unexplained hypertrophic cardiomyopathy

Professor R. Barriales-Villa (Coruna, A, ES)

Abstract Slides Video

Presentation thumbnail

SGLT2 inhibitor treatment in patients with cardiac amyloidosis

Doctor D. Lavall (Leipzig, DE)

Abstract Slides Video

Presentation thumbnail

Prognostic importance of the 6-minute walk test in transthyretin cardiac amyloidosis

Doctor A. Ioannou (Greater London, GB)

Abstract Slides Video

Presentation thumbnail

Diverse presentations of transthyretin cardiac amyloidosis beyond heart failure with preserved ejection fraction

Miss A. Achten (Maastricht, NL)

Abstract Slides Video

Access the full session

Session thumbnail

Amyloid cardiomyopathy: epidemiology, diagnosis, prognostic and treatment

The Event

Event poster

Heart Failure 2024

13 May 2024 16:51 CET

You may be interested in

Congress Session

Amyloid cardiomyopathy: epidemiology, diagnosis, prognostic and treatment

Congress Session

Cardiac amyloidosis from epidemiology to treatment

Congress Presentation

Deep phenotyping of variant ATTR amyloid cardiomyopathy associated with the p.V142I TTR variant.

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources